Physician profile
Scott A Bernstein
NPI 1689601817
$4,141.57
in general payments reported to CMS, 2019-2025
33 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $448 · 2022: $76.74 · 2023: $232 · 2024: $1,312 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Travel and Lodging: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.68 |
| Travel and Lodging | $840.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,050.40 | 2023-2025 | Evera Mri Xt Dr Surescan, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Lilly USA, LLC | $271.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $242.90 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $223.70 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.29 | 2019-2025 | Jardiance |
| Amgen INC. | $212.82 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $177.43 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $160.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $153.53 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Atricure, INC. | $139.07 | 2019 | |
| Merck Sharp & Dohme LLC | $138.21 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $122.80 | 2019-2020 | |
| Angiodynamics, INC. | $116.59 | 2023 | Angiovac |
| Amarin Pharma, INC. | $101.52 | 2019-2020 | |
| Philips North America LLC | $86.62 | 2023-2024 | (Am5) Lead Management, (9278) Bridge |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $86.08 | 2019-2025 | Eliquis |
| Boston Scientific Corporation | $79.06 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.26 | 2022-2025 | |
| Astellas Pharma US INC | $63.14 | 2024 | Veozah |
| Regeneron Healthcare Solutions, INC. | $61.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $56.28 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.35 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $52.71 | 2019-2020 | |
| Allergan, INC. | $38.81 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $34.40 | 2025 | Gore Cardioform Septal Occluder |
| Sanofi Pasteur INC. | $26.13 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.37 | 2019 | |
| Abbvie INC. | $18.05 | 2022 | |
| Circassia INC. | $17.31 | 2019 | |
| Seqirus USA INC | $15.19 | 2019 | |
| Shionogi INC | $15.12 | 2019 | |
| Abbott Laboratories | $13.01 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.